Ignite Creation Date:
2025-12-24 @ 10:35 PM
Ignite Modification Date:
2026-03-01 @ 2:45 AM
Study NCT ID:
NCT06212635
Status:
RECRUITING
Last Update Posted:
2024-01-19
First Post:
2023-02-22
Is NOT Gene Therapy:
True
Has Adverse Events:
False
Brief Title:
Hemostasis in Liver Cirrhosis and Hepatocellular Cancer
Sponsor:
Region Stockholm
Organization:
Study Overview
Official Title:
Novel Biomarkers for Evaluation of Hemostasis and Inflammation in Liver Cirrhosis
Status:
RECRUITING
Status Verified Date:
2023-02
Last Known Status:
None
Delayed Posting:
No
If Stopped, Why?:
Not Stopped
Has Expanded Access:
False
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
HELICS
Brief Summary:
Evaluating hemostasis in decompensated liver cirrhosis with novel hemostatic assays.
Detailed Description:
The rebalanced hemostasis in liver cirrhosis is vulnerable and patients are prone to both bleeding and thrombosis. There are today no gold standard for evaluating the hemostasis and we will evaluate novel methods for this.
Study Oversight
Has Oversight DMC:
False
Is a FDA Regulated Drug?:
False
Is a FDA Regulated Device?:
True
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
False
Is an FDA AA801 Violation?: